Developer · United States

Sage Therapeutics, Inc.

Cambridge, MA neuroscience company focused on brain-health medicines; developer of zuranolone (ZURZUVAE, approved for postpartum depression) and originator of the NMDA-PAM oxysterol dalzanemdor (SAGE-718), discontinued in November 2024 after Phase 2 misses in Parkinson's, Alzheimer's and Huntington's cognitive impairment. Formerly Nasdaq: SAGE; acquired by Supernus Pharmaceuticals on 2025-07-31 ($8.50/share cash plus a CVR of up to $3.50) and now operates as a wholly owned subsidiary.

sagerx.com ↗

1compound
3programs
3indications
Discontinuedlead asset

Phase distribution

  • Discontinued3

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Deals & partnerships

  • Jul 31, 2025AcquisitionSupernus Pharmaceuticals completes acquisition of Sage TherapeuticsSupernus completed its acquisition of Sage Therapeutics on 2025-07-31 ($8.50 per share in cash plus one contingent value right of up to $3.50 per share). Dalzanemdor had already been discontinued (November 2024); the deal was driven by ZURZUVAE (zuranolone). All SAGE-718 ClinicalTrials.gov records now list Supernus as lead sponsor as a result of the transfer. No revival of dalzanemdor has been announced.Dalzanemdorsource ↗

Catalysts · 0 upcoming · 4 reported

Recently reported

  • 2024-11-20missed

    DalzanemdorforHuntington's diseaseTopline data

    Phase 2 DIMENSION topline: dalzanemdor missed the primary endpoint (change from baseline in SDMT at Day 84 vs placebo; n=189) with no statistically significant or clinically meaningful secondary-endpoint differences; Sage ends all development of dalzanemdor and closes the Phase 3 open-label PURVIEW study.

    source ↗

  • 2024-10-08missed

    DalzanemdorforAlzheimer's diseaseTopline data

    Phase 2 LIGHTWAVE topline: dalzanemdor missed the primary endpoint (WAIS-IV Coding Test score vs placebo at Day 84; n=174) in mild cognitive impairment and mild dementia due to Alzheimer's disease; Sage ends dalzanemdor development in AD.

    source ↗

  • 2024-06-11mixed

    DalzanemdorforHuntington's diseaseTopline data

    Phase 2 SURVEYOR topline: primary endpoint met — a statistically significant baseline difference on the HD-CAB composite between HD participants and healthy volunteers — but only a small numerical dalzanemdor-placebo difference; well tolerated, no new safety signals.

    source ↗

  • 2024-04-16missed

    DalzanemdorforParkinson's diseaseTopline data

    Phase 2 PRECEDENT topline: dalzanemdor missed the primary endpoint (WAIS-IV Coding Test score vs placebo at Day 42; n=86) in mild cognitive impairment in Parkinson's disease; Sage stops dalzanemdor development in Parkinson's.

    source ↗

Recent activity

  • Nov 20, 2024ReadoutDalzanemdor·Huntington's diseasemissedPhase 2 DIMENSION topline: dalzanemdor missed the primary endpoint (change from baseline in SDMT at Day 84 vs placebo; n=189) with no statistically significant or clinically meaningful secondary-endpoint differences; Sage ends all development of dalzanemdor and closes the Phase 3 open-label PURVIEW study.source ↗
  • Oct 8, 2024ReadoutDalzanemdor·Alzheimer's diseasemissedPhase 2 LIGHTWAVE topline: dalzanemdor missed the primary endpoint (WAIS-IV Coding Test score vs placebo at Day 84; n=174) in mild cognitive impairment and mild dementia due to Alzheimer's disease; Sage ends dalzanemdor development in AD.source ↗
  • Jun 11, 2024ReadoutDalzanemdor·Huntington's diseasemixedPhase 2 SURVEYOR topline: primary endpoint met — a statistically significant baseline difference on the HD-CAB composite between HD participants and healthy volunteers — but only a small numerical dalzanemdor-placebo difference; well tolerated, no new safety signals.source ↗
  • Apr 16, 2024ReadoutDalzanemdor·Parkinson's diseasemissedPhase 2 PRECEDENT topline: dalzanemdor missed the primary endpoint (WAIS-IV Coding Test score vs placebo at Day 42; n=86) in mild cognitive impairment in Parkinson's disease; Sage stops dalzanemdor development in Parkinson's.source ↗
  • Nov 29, 2022Phase changeDalzanemdor·Alzheimer's diseasePhase 2Placebo-controlled Phase 2 LIGHTWAVE study (NCT05619692) started: 12-week, randomized, double-blind study of once-daily dalzanemdor in MCI or mild dementia due to AD; primary endpoint WAIS-IV Coding Test at Day 84; 174 enrolled.source ↗
  • Jun 6, 2022Phase changeDalzanemdor·Parkinson's diseasePhase 2Placebo-controlled Phase 2 PRECEDENT study (NCT05318937) started: double-blind study of once-daily oral dalzanemdor in adults with PD-MCI; primary endpoint WAIS-IV Coding Test at Day 42; 86 enrolled.source ↗
  • Jan 26, 2022Phase changeDalzanemdor·Huntington's diseasePhase 2Phase 2 DIMENSION study (NCT05107128) started: 12-week, double-blind, placebo-controlled study of dalzanemdor in participants with cognitive impairment associated with HD; primary endpoint change from baseline in SDMT at Day 84; 189 randomized. The 28-day Phase 2 SURVEYOR study (NCT05358821) followed on 2022-05-26 and the Phase 3 open-label safety study PURVIEW (NCT05655520) on 2022-12-14 — PURVIEW is registered Phase 3 but is an open-label safety study, so it is deliberately not treated as a phase advance here.source ↗
  • Dec 7, 2020Phase changeDalzanemdor·Alzheimer's diseasePhase 2Phase 2a open-label safety and tolerability study LUMINARY (NCT04602624) started in participants with MCI or mild dementia due to AD (n=26; completed 2021-09-28).source ↗
  • Jul 31, 2020Phase changeDalzanemdor·Parkinson's diseasePhase 2Phase 2 open-label safety and tolerability study PARADIGM (NCT04476017) started in participants with Parkinson's disease mild cognitive impairment (n=18; completed 2022-03-25).source ↗
  • Feb 28, 2019Phase changeDalzanemdor·Huntington's diseasePhase 1First patient study in Huntington's disease: NCT03787758, a Phase 1 open-label safety/tolerability/PK study of SAGE-718 oral solution in HD patients (Part B, n=6), started per ClinicalTrials.gov.source ↗

Competitive landscape

Other companies developing against Sage Therapeutics, Inc.'s targets or indications.